A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy

Pietro Annovazzi, Valentina Tomassini, Benedetta Bodini, Laura Boffa, Massimiliano Calabrese, Eleonora Cocco, Cinzia Cordioli, Giovanna De Luca, Giovanni Frisullo, Antonio Gallo, Simona Malucchi, Damiano Paolicelli, Ilaria Pesci, Marta Radaelli, Paolo Ragonese, Luca Roccatagliata, Carla Tortorella, Marco Vercellino, Valentina Zipoli, Claudio Gasperini & 2 others Mariaemma Rodegher, Claudio Solaro

Research output: Contribution to journalArticle

Abstract

Despite the existence of therapeutic guidelines, management of multiple sclerosis relapse remains heterogeneous. Optimisation of relapse outcome demands an improved understanding of the neurologist's therapeutic attitude towards relapse management, which is the aim of this study. Neurologists from 13 multiple sclerosis centres completed a questionnaire every time they assessed multiple sclerosis relapses. The questionnaire requested a guided description of the relapse's clinical characteristics and an indication of the prescribed therapy, supported with up to 3 out of 20 suggested reasons. Over 3 months, 368 questionnaires were collected. Median percentage (%) of 21 relapses resulting in a prescription was 88.9%. Corticosteroids represented the most frequent prescription. A short-course of high-dose intravenous methylprednisolone was the most used corticosteroid (73.7%). Treatment was administrated mainly in day case unit (80.0%) and at home (13.6%). A tapered therapy was prescribed to 28.8% of patients. Neurologists' therapeutic decisions were driven mainly by relapse severity (45.3%) and symptom evolution (24.2%). Our study confirms the therapeutic attitude of multiple sclerosis specialists in treating relapses with high-dose intravenous corticosteroids in a day hospital setting, with a tapering in a proportion of cases. The main reasons for prescription are relapse severity and symptom evolution.

Original languageEnglish
Pages (from-to)197-203
Number of pages7
JournalNeurological Sciences
Volume34
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Italy
Multicenter Studies
Multiple Sclerosis
Cross-Sectional Studies
Recurrence
Prescriptions
Adrenal Cortex Hormones
Therapeutics
Methylprednisolone
Guidelines
Neurologists
Surveys and Questionnaires

Keywords

  • Corticosteroids
  • Management
  • Multiple sclerosis
  • Relapse
  • Survey

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Annovazzi, P., Tomassini, V., Bodini, B., Boffa, L., Calabrese, M., Cocco, E., ... Solaro, C. (2013). A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. Neurological Sciences, 34(2), 197-203. https://doi.org/10.1007/s10072-012-0981-5

A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. / Annovazzi, Pietro; Tomassini, Valentina; Bodini, Benedetta; Boffa, Laura; Calabrese, Massimiliano; Cocco, Eleonora; Cordioli, Cinzia; De Luca, Giovanna; Frisullo, Giovanni; Gallo, Antonio; Malucchi, Simona; Paolicelli, Damiano; Pesci, Ilaria; Radaelli, Marta; Ragonese, Paolo; Roccatagliata, Luca; Tortorella, Carla; Vercellino, Marco; Zipoli, Valentina; Gasperini, Claudio; Rodegher, Mariaemma; Solaro, Claudio.

In: Neurological Sciences, Vol. 34, No. 2, 02.2013, p. 197-203.

Research output: Contribution to journalArticle

Annovazzi, P, Tomassini, V, Bodini, B, Boffa, L, Calabrese, M, Cocco, E, Cordioli, C, De Luca, G, Frisullo, G, Gallo, A, Malucchi, S, Paolicelli, D, Pesci, I, Radaelli, M, Ragonese, P, Roccatagliata, L, Tortorella, C, Vercellino, M, Zipoli, V, Gasperini, C, Rodegher, M & Solaro, C 2013, 'A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy', Neurological Sciences, vol. 34, no. 2, pp. 197-203. https://doi.org/10.1007/s10072-012-0981-5
Annovazzi, Pietro ; Tomassini, Valentina ; Bodini, Benedetta ; Boffa, Laura ; Calabrese, Massimiliano ; Cocco, Eleonora ; Cordioli, Cinzia ; De Luca, Giovanna ; Frisullo, Giovanni ; Gallo, Antonio ; Malucchi, Simona ; Paolicelli, Damiano ; Pesci, Ilaria ; Radaelli, Marta ; Ragonese, Paolo ; Roccatagliata, Luca ; Tortorella, Carla ; Vercellino, Marco ; Zipoli, Valentina ; Gasperini, Claudio ; Rodegher, Mariaemma ; Solaro, Claudio. / A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy. In: Neurological Sciences. 2013 ; Vol. 34, No. 2. pp. 197-203.
@article{c3f4387e58224f118f1b6f7c2fa1a076,
title = "A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy",
abstract = "Despite the existence of therapeutic guidelines, management of multiple sclerosis relapse remains heterogeneous. Optimisation of relapse outcome demands an improved understanding of the neurologist's therapeutic attitude towards relapse management, which is the aim of this study. Neurologists from 13 multiple sclerosis centres completed a questionnaire every time they assessed multiple sclerosis relapses. The questionnaire requested a guided description of the relapse's clinical characteristics and an indication of the prescribed therapy, supported with up to 3 out of 20 suggested reasons. Over 3 months, 368 questionnaires were collected. Median percentage ({\%}) of 21 relapses resulting in a prescription was 88.9{\%}. Corticosteroids represented the most frequent prescription. A short-course of high-dose intravenous methylprednisolone was the most used corticosteroid (73.7{\%}). Treatment was administrated mainly in day case unit (80.0{\%}) and at home (13.6{\%}). A tapered therapy was prescribed to 28.8{\%} of patients. Neurologists' therapeutic decisions were driven mainly by relapse severity (45.3{\%}) and symptom evolution (24.2{\%}). Our study confirms the therapeutic attitude of multiple sclerosis specialists in treating relapses with high-dose intravenous corticosteroids in a day hospital setting, with a tapering in a proportion of cases. The main reasons for prescription are relapse severity and symptom evolution.",
keywords = "Corticosteroids, Management, Multiple sclerosis, Relapse, Survey",
author = "Pietro Annovazzi and Valentina Tomassini and Benedetta Bodini and Laura Boffa and Massimiliano Calabrese and Eleonora Cocco and Cinzia Cordioli and {De Luca}, Giovanna and Giovanni Frisullo and Antonio Gallo and Simona Malucchi and Damiano Paolicelli and Ilaria Pesci and Marta Radaelli and Paolo Ragonese and Luca Roccatagliata and Carla Tortorella and Marco Vercellino and Valentina Zipoli and Claudio Gasperini and Mariaemma Rodegher and Claudio Solaro",
year = "2013",
month = "2",
doi = "10.1007/s10072-012-0981-5",
language = "English",
volume = "34",
pages = "197--203",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "2",

}

TY - JOUR

T1 - A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy

AU - Annovazzi, Pietro

AU - Tomassini, Valentina

AU - Bodini, Benedetta

AU - Boffa, Laura

AU - Calabrese, Massimiliano

AU - Cocco, Eleonora

AU - Cordioli, Cinzia

AU - De Luca, Giovanna

AU - Frisullo, Giovanni

AU - Gallo, Antonio

AU - Malucchi, Simona

AU - Paolicelli, Damiano

AU - Pesci, Ilaria

AU - Radaelli, Marta

AU - Ragonese, Paolo

AU - Roccatagliata, Luca

AU - Tortorella, Carla

AU - Vercellino, Marco

AU - Zipoli, Valentina

AU - Gasperini, Claudio

AU - Rodegher, Mariaemma

AU - Solaro, Claudio

PY - 2013/2

Y1 - 2013/2

N2 - Despite the existence of therapeutic guidelines, management of multiple sclerosis relapse remains heterogeneous. Optimisation of relapse outcome demands an improved understanding of the neurologist's therapeutic attitude towards relapse management, which is the aim of this study. Neurologists from 13 multiple sclerosis centres completed a questionnaire every time they assessed multiple sclerosis relapses. The questionnaire requested a guided description of the relapse's clinical characteristics and an indication of the prescribed therapy, supported with up to 3 out of 20 suggested reasons. Over 3 months, 368 questionnaires were collected. Median percentage (%) of 21 relapses resulting in a prescription was 88.9%. Corticosteroids represented the most frequent prescription. A short-course of high-dose intravenous methylprednisolone was the most used corticosteroid (73.7%). Treatment was administrated mainly in day case unit (80.0%) and at home (13.6%). A tapered therapy was prescribed to 28.8% of patients. Neurologists' therapeutic decisions were driven mainly by relapse severity (45.3%) and symptom evolution (24.2%). Our study confirms the therapeutic attitude of multiple sclerosis specialists in treating relapses with high-dose intravenous corticosteroids in a day hospital setting, with a tapering in a proportion of cases. The main reasons for prescription are relapse severity and symptom evolution.

AB - Despite the existence of therapeutic guidelines, management of multiple sclerosis relapse remains heterogeneous. Optimisation of relapse outcome demands an improved understanding of the neurologist's therapeutic attitude towards relapse management, which is the aim of this study. Neurologists from 13 multiple sclerosis centres completed a questionnaire every time they assessed multiple sclerosis relapses. The questionnaire requested a guided description of the relapse's clinical characteristics and an indication of the prescribed therapy, supported with up to 3 out of 20 suggested reasons. Over 3 months, 368 questionnaires were collected. Median percentage (%) of 21 relapses resulting in a prescription was 88.9%. Corticosteroids represented the most frequent prescription. A short-course of high-dose intravenous methylprednisolone was the most used corticosteroid (73.7%). Treatment was administrated mainly in day case unit (80.0%) and at home (13.6%). A tapered therapy was prescribed to 28.8% of patients. Neurologists' therapeutic decisions were driven mainly by relapse severity (45.3%) and symptom evolution (24.2%). Our study confirms the therapeutic attitude of multiple sclerosis specialists in treating relapses with high-dose intravenous corticosteroids in a day hospital setting, with a tapering in a proportion of cases. The main reasons for prescription are relapse severity and symptom evolution.

KW - Corticosteroids

KW - Management

KW - Multiple sclerosis

KW - Relapse

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=84879693371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879693371&partnerID=8YFLogxK

U2 - 10.1007/s10072-012-0981-5

DO - 10.1007/s10072-012-0981-5

M3 - Article

VL - 34

SP - 197

EP - 203

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 2

ER -